Portal de recerca
- Inici
- Projectes i Estudis Clínics
- Estudio de fase IIa, multicéntrico, doble ciego (participante e investigador), aleatorizado y controlado con placebo en el que se investigan la farmacocinética, la farmacodinámica, la seguridad y la tolerabilidad de TIN816 en el tratamiento de pacientes con lesión renal aguda asociada a sepsis.
Estudio de fase IIa, multicéntrico, doble ciego (participante e investigador), aleatorizado y controlado con placebo en el que se investigan la farmacocinética, la farmacodinámica, la seguridad y la tolerabilidad de TIN816 en el tratamiento de pacientes con lesión renal aguda asociada a sepsis.
Dades bàsiques
- Protocol:
- CTIN816B12201
- EURDRACT:
- 2022-000887-23
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2022
- Any de finalització:
- 2024
Objectius del projecte
Objetivo Principal: Determinar el perfil farmacocinético de TIN816 Objetivos Secundarios: Evaluar la seguridad y tolerabilidad de TIN816 frente a placebo
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
"INTUPROS": una oportunidad para reflexionar y mejorar.
Viviani, Andrea, Vicent, Carlos, Castellanos-Ortega, Alvaro
Letter. 10.1016/j.medine.2024.04.014. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
Anti-endotoxin antibodies consumption in cardiovascular collapse: Pathophysiological concerns.
Villarreal, E.; (...); Vila, J.
Article. 10.1016/j.medine.2022.04.019. 2022
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Endothelial Damage, Neutrophil Extracellular Traps and Platelet Activation in COVID-19 vs. Community-Acquired Pneumonia: A Case-Control Study.
González-Jiménez P; (...); Menéndez R
Article. 10.3390/ijms241713194. 2023
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Provencio M; (...); Calvo V
Article. 10.1016/j.lungcan.2023.107323. 2023
Initial and Residual Cardiovascular Damage Remaining at Day 30 in Community-acquired Pneumonia
Ocana, R. Mendez; (...); Menendez, R.
Meeting Abstract. https://doi.org/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A6241. 2024
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Mentoring Programme: Guiding your first steps towards scientific excellence
Lobo-Valbuena, Beatriz; (...); Ortega, Alvaro Castellanos
Article. 10.1016/j.medin.2023.02.007. 2023
Mentoring Programme: Guiding your first steps towards scientific excellence.
Lobo-Valbuena B; (...); Castellanos Ortega Á
Article. 10.1016/j.medine.2023.03.006. 2023
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Neutrophil Extracellular Traps and Platelet Activation for Identifying Severe Episodes and Clinical Trajectories in COVID-19
González-Jiménez P; (...); Menéndez R
Article. 10.3390/ijms24076690. 2023
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Patient safety, what does clinical simulation and teaching innovation contribute?
Broch Porcar, Maria Jesus, Castellanos-Ortega, Alvaro
Article. 10.1016/j.medine.2024.04.012. 2024
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
The Role of Cell Cycle Arrest Biomarkers for Predicting Acute Kidney Injury in Critically Ill COVID-19 Patients: A Multicenter, Observational Study.
Weiss R; (...); Zarbock A
Article. 10.1097/CCM.0000000000005853. 2023
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023